share_log

Investors in West Pharmaceutical Services (NYSE:WST) Have Seen Strong Returns of 107% Over the Past Five Years

Investors in West Pharmaceutical Services (NYSE:WST) Have Seen Strong Returns of 107% Over the Past Five Years

西部藥品服務公司(紐交所:WST)的投資者在過去五年中獲得了強勁的回報,達到了107%。
Simply Wall St ·  08/23 18:24

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you can make far more than 100% on a really good stock. For instance, the price of West Pharmaceutical Services, Inc. (NYSE:WST) stock is up an impressive 104% over the last five years. Meanwhile the share price is 2.7% higher than it was a week ago.

任何一隻股票的最大虧損(假設您沒有使用槓桿)是您的全部資金的100%。但好消息是,您可以在一隻非常好的股票上賺取遠遠超過100%的回報。例如,西部藥業服務公司(NYSE:WST)的股價在過去五年中上漲了驚人的104%。同時,股價比一週前上漲了2.7%。

Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns.

讓我們長期看一下潛在的基本面,看看它們是否與股東回報一致。

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

儘管一些人繼續教授有效市場假說,但已經證明市場是過度反應的動態系統,並且投資者並不總是理性的。通過比較每股收益(EPS)和股價的變化情況,我們可以了解投資者對公司的態度如何隨着時間變化而變化。

Over half a decade, West Pharmaceutical Services managed to grow its earnings per share at 19% a year. This EPS growth is higher than the 15% average annual increase in the share price. Therefore, it seems the market has become relatively pessimistic about the company.

在過去五年中,西部藥業服務公司的每股收益年均增長了19%。這種每股收益增長高於股價的平均年增長率15%。因此,市場對該公司變得相對悲觀。

The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).

該公司的每股收益(隨時間的推移)如下圖所示(單擊可查看確切數字)。

1724408639573
NYSE:WST Earnings Per Share Growth August 23rd 2024
紐交所:WSt每股收益增長2024年8月23日

Dive deeper into West Pharmaceutical Services' key metrics by checking this interactive graph of West Pharmaceutical Services's earnings, revenue and cash flow.

通過查看西美研究所的收入、營業收入和現金流的交互式圖表,深入了解西美研究所的關鍵指標。

What About Dividends?

那麼分紅怎麼樣呢?

As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. As it happens, West Pharmaceutical Services' TSR for the last 5 years was 107%, which exceeds the share price return mentioned earlier. The dividends paid by the company have thusly boosted the total shareholder return.

除了衡量股價回報外,投資者還應考慮股東總回報(TSR)。TSR是一種回報計算,考慮了現金股利的價值(假設任何收到的股利都被再投資)以及任何折扣後的增資和剝離的計算價值。因此,對於支付豐厚股利的公司,TSR往往比股價回報高得多。事實上,西美研究所過去5年的TSR爲107%,超過了前面提到的股價回報。公司支付的股利因此提升了股東總回報。

A Different Perspective

不同的觀點

While the broader market gained around 27% in the last year, West Pharmaceutical Services shareholders lost 23% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 16% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling.

儘管整體市場去年上漲約27%,西美研究所的股東卻損失了23%(包括股利)。即使優質股票的股價有時也會下跌,但我們希望在對業務的基本指標產生興趣之前,看到業務的基本指標有所改善。值得一提的是,長期股東們賺了錢,過去半個世紀的年均增長率爲16%。最近的拋售行爲可能是一個機會,因此看看基本數據是否顯示出長期增長趨勢可能是值得的。大多數投資者都會花時間檢查內部交易數據。您可以單擊此處查看內部人員是否一直在買賣。

But note: West Pharmaceutical Services may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

但請注意:West Pharmaceutical Services可能不是最適合買入的股票。因此,請查看這個免費的有過去盈利增長(以及更進一步增長預測)的有趣公司名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論